Contraceptive Use and Respiratory Conditions Among Scottish Women

Use of Hormonal Contraceptives in Relation to Asthma and Wheezing Disorders in Scottish Women: a Population-based Cross-sectional Survey

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02039102

Enrollment

3257

Registered

2014-01-17

Start date

2013-12-31

Completion date

2018-09-30

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

hormonal contraceptives, combined pills, progesterone-only contraceptives, body mass index, asthma, Scotland, women

Brief summary

Studies examining the sex differences in the epidemiology and morbidity patterns of asthma show that the rates of disease severity, healthcare utilisation, and poor quality of life are considerably higher in women than in men, and this has been attributed to endogenous and exogenous sex hormonal factors. Studies examining the impact of use of hormonal contraceptives on the risk of asthma and asthma-related conditions are few, yet findings are conflicting. In the present study, the investigators utilize data from the Scottish Health Survey, a national representative sample, to investigate the associations between current use of hormonal contraceptives and the prevalence of self-reported doctor-diagnosed current asthma and wheezing symptoms in Scottish women. The investigators hypothesize that while current use of any hormonal contraceptives and combined oral pills are associated with higher prevalence of asthma and asthma outcomes, current use of progesterone-only contraceptives is not associated with asthma. A secondary aim of the current study is to examine whether there is evidence of any biological interaction between use of hormonal contraceptives and BMI in relation to the risk of asthma and asthma outcomes.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

16 Years to 45 Years

Inclusion criteria

* Non-pregnant * Woman * 16-45 years old

Exclusion criteria

* Pregnant * Man * Younger than 16 years or older than 45 years old

Design outcomes

Primary

Measure	Time frame
Self-reported doctor-diagnosed current asthma	During the past 12 months

Secondary

Measure	Time frame
Self-reported wheezing symptom	During the past 12 months
Self-reported current treatment for asthma/wheeze	During the past 12 months

Countries

United Kingdom

Outcome results